Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies

You are currently viewing Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies

Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies

Post published:June 8, 2022
Post category:Press Release

His talk will kick-off the daylong biotechnology conference on cutting-edge therapies

His talk will kick-off the daylong biotechnology conference on cutting-edge therapies

Source link

Tags: Wesana Health

Leave a Reply Cancel reply

Psychedelic Funding Update: Q3 2024October 8, 2024
We review psychedelic company financing activity in Q3 2024, which marked a significant slow-down in investment from both Q1 and Q2. Despite this downturn, two private companies, Sunstone Therapies and Soneira Bio raised during the quarter, along with a half-dozen public companies that completed modest private placements. Here, we present updated financing charts and brief analysis.
Pα+ Psychedelic Bulletin #175: atai Sells a Third of Compass Stake; Lykos’ Unproven Psychotherapy Hampered Studies, Claim Academics; Picking PlacebosOctober 4, 2024
atai Sells a Third of Compass Stake to Raise Cash for In-House Programs • Lykos’ Unproven Psychotherapy Hampered Studies, Claim Authors of New Viewpoint • Picking Placebos for Psychedelic Studies • Small Study of Psilocybin in Severe TRD Among Veterans Shows Promise, But Authors Encourage Tempering Expectations • and more...
The Psychedelics Lobby: Tracking Federal Lobbying by Psychedelics Companies and NonprofitsSeptember 30, 2024
With just over one month to go until the U.S. elections, we take a look at federal lobbying on psychedelics-related matters. Here, we collate data on formal lobbying activity among psychedelic drug developers and nonprofits, which have collectively funnelled over $1.5 million into such efforts in the last two years.
Pα+ Psychedelic Bulletin #174: Psilocybin Outperforms Escitalopram After 6 Months… or Does It? Survey Results Reveal Healthcare Practitioner Attitudes to Psychedelics; and more…September 27, 2024
Six-Month Follow-Up Data Shows Psilocybin Outperforms Escitalopram… or Does It? • Survey Reveals Healthcare Practitioner Attitudes to Psychedelics • MIND Foundation Plots 700-Patient Psilocybin Study • Beckley Psytech-affiliated Study of Low-Dose Psilocybin for Headache Disorder Terminated Due to Recruitment Difficulties • and more...
The Psychedelic News Feed: March 4, 2024 – September 1, 2024September 23, 2024
This is an archived version of our Psychedelic News Feed, from March 4, 2024 - September 1, 2024.

Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies

Leave a Reply Cancel reply

Psychedelic Alpha

Quick Links

Newsletter

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

You Might Also Like

Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)

Bexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation

Champignon Brands ($SHRM) Trading Halt

Leave a Reply Cancel reply

Psychedelic Alpha

Quick Links

Newsletter

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights